Takeda Pharmaceutical (NYSE:TAK) Posts Earnings Results, Beats Expectations By $0.37 EPS

Takeda Pharmaceutical (NYSE:TAK) issued its quarterly earnings data on Thursday. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.14 by $0.37, Zacks reports. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The firm had revenue of $7.53 billion for the quarter, compared to analyst estimates of $7.34 billion.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Takeda reported first-half core revenue of JPY 2.4 trillion, down 1% at constant exchange rates, while core operating profit rose 0.7% to JPY 710.6 billion. Full-year revenue guidance remains a low-single-digit decline, but core operating profit and EPS guidance were raised primarily due to favorable foreign exchange.
• Takeda has launched ORZEYFUL in Japan and China and expects a U.S. launch in early November, while MIMRYLO launched in the U.S. in August and is receiving positive physician and patient feedback. Zasocitinib filings were accepted for priority review in the U.S. and by European regulators, supporting potential approval and launch in fiscal 2026.
• The company’s transformation program is progressing, with approximately 3,000 impacted roles communicated and JPY 30 billion in annualized procurement savings implemented. Takeda remains on track for JPY 100 billion in gross savings, which management says is helping fund product launches and R&D investment.
• Late-stage pipeline data were encouraging: TAK-921 produced statistically significant progression-free and overall survival benefits in heavily pretreated gastric cancer, including an overall survival hazard ratio of 0.57, while ENTYVIO’s VERDICT study showed roughly a 70% reduction in ulcerative-colitis-related complications for patients treated to stringent targets.
• Zasocitinib’s ulcerative colitis study showed encouraging efficacy at the 50 mg dose, but not at 75 mg, creating uncertainty because there was no clear dose-response relationship; Takeda will wait for Crohn’s disease data expected around fiscal year-end before finalizing its phase III strategy. Plasma-derived therapies also faced near-term weakness in IVIG and albumin, with albumin forecasts reduced due to market conditions and Chinese cost-containment measures.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock traded up $0.92 during midday trading on Friday, reaching $20.93. The company’s stock had a trading volume of 4,540,829 shares, compared to its average volume of 3,021,581. The firm has a market capitalization of $67.05 billion, a PE ratio of 61.54 and a beta of -0.07. Takeda Pharmaceutical has a fifty-two week low of $13.35 and a fifty-two week high of $21.22. The stock’s 50 day simple moving average is $18.79 and its 200 day simple moving average is $17.52. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14.

Insider Buying and Selling

In related news, insider Andrew Plump sold 116,191 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $18.49, for a total value of $2,148,371.59. Following the sale, the insider directly owned 145,465 shares in the company, valued at $2,689,647.85. The trade was a 44.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lauren Duprey sold 34,535 shares of the business’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the transaction, the insider directly owned 191,522 shares of the company’s stock, valued at approximately $3,550,817.88. This trade represents a 15.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 627,457 shares of company stock valued at $10,981,175 in the last three months. 0.04% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TAK shares. Zacks Research downgraded Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 1st. Weiss Ratings upgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Key Headlines Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda reported quarterly adjusted earnings of approximately $0.48 per share, ahead of the $0.31 consensus estimate, while reported EPS was $0.51 versus expectations of $0.14. Revenue reached $7.53 billion, exceeding the $7.34 billion consensus. Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
• Positive Sentiment: The company raised its annual guidance after first-half profit growth, providing a near-term catalyst and signaling confidence in operating execution despite a generic-drug overhang. Takeda Pharmaceutical Raises Annual Guidance
• Positive Sentiment: Takeda secured approvals for ORZEYFUL (oveporexton) in the U.S., Japan and China, launched MIMRYLO (rusfertide) in the U.S., and advanced zasocitinib’s regulatory review. Management is targeting roughly $11 billion in peak sales from a trio of blockbuster candidates, supporting the longer-term growth story. Takeda Announces FY2026 First-Half Results Takeda Bets on Blockbuster Drug Trio
• Neutral Sentiment: Operating margin improved to 17%, partly because of lower amortization costs. However, Entyvio remains the primary revenue driver, while newer products have so far contributed only modestly as they ramp. Takeda Pharmaceutical’s Earnings Growth Has Yet to Translate to Higher Cash Flow
• Negative Sentiment: Operating cash flow declined to $2.74 billion, raising questions about the quality and durability of earnings. Analysts also cited the difficulty of replacing major drug revenues and viewed the current valuation as limiting upside, leading to a Hold stance. Cash Flow and Valuation Concerns

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.